tiprankstipranks
Bio-Techne (TECH)
NASDAQ:TECH
US Market
TECH
Bio-Techne
RESEARCH TOOLSreports
Want to see TECH full AI Analyst Report?

Bio-Techne (TECH) Stock Forecast & Price Target

530 Followers
See the Price Targets and Ratings of:

TECH Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
6 Buy
4 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Bio-Techne
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TECH Stock 12 Month Forecast

Average Price Target

$59.25
▲(0.03% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $59.25 with a high forecast of $70.00 and a low forecast of $49.00. The average price target represents a 0.03% change from the last price of $59.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","53":"$53","59":"$59","65":"$65","71":"$71"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$49.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,53,59,65,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.918,56.078153846153846,57.23830769230769,58.39846153846154,59.558615384615386,60.71876923076923,61.87892307692308,63.03907692307692,64.19923076923077,65.35938461538461,66.51953846153846,67.6796923076923,68.83984615384615,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.918,55.251230769230766,55.58446153846154,55.917692307692306,56.25092307692308,56.584153846153846,56.91738461538461,57.25061538461539,57.58384615384615,57.91707692307692,58.25030769230769,58.58353846153846,58.91676923076923,{"y":59.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.918,54.46276923076923,54.00753846153846,53.55230769230769,53.09707692307692,52.64184615384615,52.186615384615386,51.73138461538461,51.276153846153846,50.82092307692308,50.365692307692306,49.91046153846154,49.455230769230766,{"y":49,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.251,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.317,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.766,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.559,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.382,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.648,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.286,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.556,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.622,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.041,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.713,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.381,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.918,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$59.25Lowest Price Target$49.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on TECH
Dan Leonard
RBC Capital
RBC Capital
$62
Buy
4.68%
Upside
Initiated
05/14/26
Bio-Techne resumed with an Outperform at RBC CapitalBio-Techne resumed with an Outperform at RBC Capital
Deutsche Bank Analyst forecast on TECH
Justin Bowers
Deutsche Bank
Deutsche Bank
$75→$66
Buy
11.43%
Upside
Reiterated
05/08/26
Bio-Techne price target lowered to $66 from $75 at Deutsche BankBio-Techne price target lowered to $66 from $75 at Deutsche Bank
Wells Fargo Analyst forecast on TECH
Brandon Couillard
Wells Fargo
Wells Fargo
$76→$62
Buy
4.68%
Upside
Reiterated
05/07/26
Bio-Techne price target lowered to $62 from $76 at Wells FargoBio-Techne price target lowered to $62 from $76 at Wells Fargo
Robert W. Baird Analyst forecast on TECH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$70→$49
Hold
-17.27%
Downside
Reiterated
05/07/26
Bio-Techne price target lowered to $49 from $70 at BairdBio-Techne price target lowered to $49 from $70 at Baird
Citi Analyst forecast on TECH
Patrick B Donnelly
Citi
Citi
$80→$70
Buy
18.18%
Upside
Reiterated
05/07/26
Bio-Techne price target lowered to $70 from $80 at CitiBio-Techne price target lowered to $70 from $80 at Citi
KeyBanc Analyst forecast on TECH
Paul Knight
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and Bio-Techne (NASDAQ: TECH)
Stifel Nicolaus Analyst forecast on TECH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$65→$50
Hold
-15.58%
Downside
Reiterated
05/07/26
Bio-Techne price target lowered to $50 from $65 at StifelBio-Techne price target lowered to $50 from $65 at Stifel
Evercore ISI Analyst forecast on TECH
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$54→$50
Hold
-15.58%
Downside
Assigned
05/07/26
Bio-Techne price target lowered to $50 from $54 at Evercore ISIBio-Techne price target lowered to $50 from $54 at Evercore ISI
William Blair Analyst forecast on TECH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
TD Cowen Analyst forecast on TECH
Kyle Boucher
TD Cowen
TD Cowen
$65
Buy
9.74%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and InMode (NASDAQ: INMD)
Argus Research Analyst forecast on TECH
David Toung
Argus Research
Argus Research
$65→$68
Buy
14.81%
Upside
Assigned
11/20/25
Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus
Scotiabank Analyst forecast on TECH
Sung Ji Nam
Scotiabank
Scotiabank
$75
Buy
26.63%
Upside
Reiterated
08/08/25
Bio-Techne (TECH) Gets a Buy from Scotiabank
Benchmark Co. Analyst forecast on TECH
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75
Buy
26.63%
Upside
Reiterated
08/07/25
Leerink Partners Analyst forecast on TECH
Puneet Souda
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne
Stephens Analyst forecast on TECH
Steven Etoch
Stephens
Stephens
$65
Buy
9.74%
Upside
Initiated
07/21/25
Bio-Techne resumed with an Overweight at StephensBio-Techne resumed with an Overweight at Stephens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on TECH
Dan Leonard
RBC Capital
RBC Capital
$62
Buy
4.68%
Upside
Initiated
05/14/26
Bio-Techne resumed with an Outperform at RBC CapitalBio-Techne resumed with an Outperform at RBC Capital
Deutsche Bank Analyst forecast on TECH
Justin Bowers
Deutsche Bank
Deutsche Bank
$75→$66
Buy
11.43%
Upside
Reiterated
05/08/26
Bio-Techne price target lowered to $66 from $75 at Deutsche BankBio-Techne price target lowered to $66 from $75 at Deutsche Bank
Wells Fargo Analyst forecast on TECH
Brandon Couillard
Wells Fargo
Wells Fargo
$76→$62
Buy
4.68%
Upside
Reiterated
05/07/26
Bio-Techne price target lowered to $62 from $76 at Wells FargoBio-Techne price target lowered to $62 from $76 at Wells Fargo
Robert W. Baird Analyst forecast on TECH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$70→$49
Hold
-17.27%
Downside
Reiterated
05/07/26
Bio-Techne price target lowered to $49 from $70 at BairdBio-Techne price target lowered to $49 from $70 at Baird
Citi Analyst forecast on TECH
Patrick B Donnelly
Citi
Citi
$80→$70
Buy
18.18%
Upside
Reiterated
05/07/26
Bio-Techne price target lowered to $70 from $80 at CitiBio-Techne price target lowered to $70 from $80 at Citi
KeyBanc Analyst forecast on TECH
Paul Knight
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and Bio-Techne (NASDAQ: TECH)
Stifel Nicolaus Analyst forecast on TECH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$65→$50
Hold
-15.58%
Downside
Reiterated
05/07/26
Bio-Techne price target lowered to $50 from $65 at StifelBio-Techne price target lowered to $50 from $65 at Stifel
Evercore ISI Analyst forecast on TECH
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$54→$50
Hold
-15.58%
Downside
Assigned
05/07/26
Bio-Techne price target lowered to $50 from $54 at Evercore ISIBio-Techne price target lowered to $50 from $54 at Evercore ISI
William Blair Analyst forecast on TECH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
TD Cowen Analyst forecast on TECH
Kyle Boucher
TD Cowen
TD Cowen
$65
Buy
9.74%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and InMode (NASDAQ: INMD)
Argus Research Analyst forecast on TECH
David Toung
Argus Research
Argus Research
$65→$68
Buy
14.81%
Upside
Assigned
11/20/25
Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus
Scotiabank Analyst forecast on TECH
Sung Ji Nam
Scotiabank
Scotiabank
$75
Buy
26.63%
Upside
Reiterated
08/08/25
Bio-Techne (TECH) Gets a Buy from Scotiabank
Benchmark Co. Analyst forecast on TECH
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75
Buy
26.63%
Upside
Reiterated
08/07/25
Leerink Partners Analyst forecast on TECH
Puneet Souda
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne
Stephens Analyst forecast on TECH
Steven Etoch
Stephens
Stephens
$65
Buy
9.74%
Upside
Initiated
07/21/25
Bio-Techne resumed with an Overweight at StephensBio-Techne resumed with an Overweight at Stephens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Techne

3 Months
Robert WassermanBenchmark Co.
Success Rate
11/16 ratings generated profit
69%
Average Return
+2.46%
Copying Robert Wasserman's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +2.46% per trade.
1 Year
Robert WassermanBenchmark Co.
Success Rate
5/16 ratings generated profit
31%
Average Return
-3.35%
Copying Robert Wasserman's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -3.35% per trade.
2 Years
Patrick B DonnellyCiti
Success Rate
4/10 ratings generated profit
40%
Average Return
+0.73%
Copying Patrick B Donnelly's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +0.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TECH Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
1
1
1
Buy
8
8
7
5
8
Hold
3
4
4
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
12
12
10
14
In the current month, TECH has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. TECH average Analyst price target in the past 3 months is 59.25.
Each month's total comprises the sum of three months' worth of ratings.

TECH Financial Forecast

TECH Earnings Forecast

Next quarter’s earnings estimate for TECH is $0.52 with a range of $0.51 to $0.54. The previous quarter’s EPS was $0.53. TECH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.
Next quarter’s earnings estimate for TECH is $0.52 with a range of $0.51 to $0.54. The previous quarter’s EPS was $0.53. TECH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.

TECH Sales Forecast

Next quarter’s sales forecast for TECH is $315.73M with a range of $310.80M to $329.14M. The previous quarter’s sales results were $311.42M. TECH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.
Next quarter’s sales forecast for TECH is $315.73M with a range of $310.80M to $329.14M. The previous quarter’s sales results were $311.42M. TECH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.

TECH Stock Forecast FAQ

What is TECH’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Techne’s 12-month average price target is 59.25.
    What is TECH’s upside potential, based on the analysts’ average price target?
    Bio-Techne has 0.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TECH a Buy, Sell or Hold?
          Bio-Techne has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Bio-Techne’s price target?
            The average price target for Bio-Techne is 59.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $49.00. The average price target represents 0.03% Increase from the current price of $59.23.
              What do analysts say about Bio-Techne?
              Bio-Techne’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of TECH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.